@article{b036dd01a7fb43b8b91b37bec0d69414,
title = "Gelling hypotonic polymer solution for extended topical drug delivery to the eye",
abstract = "Eye-drop formulations should hold as high a concentration of soluble drug in contact with ocular epithelium for as long as possible. However, eye tears and frequent blinking limit drug retention on the ocular surface, and gelling drops typically form clumps that blur vision. Here, we describe a gelling hypotonic solution containing a low concentration of a thermosensitive triblock copolymer for extended ocular drug delivery. On topical application, the hypotonic formulation forms a highly uniform and clear thin layer that conforms to the ocular surface and resists clearance from blinking, increasing the intraocular absorption of hydrophilic and hydrophobic drugs and extending the drug–ocular-epithelium contact time with respect to conventional thermosensitive gelling formulations and commercial eye drops. We also show that the conformal gel layer allows for therapeutically relevant drug delivery to the posterior segment of the eyeball in pigs. Our findings highlight the importance of formulations that conform to the ocular surface before viscosity enhancement for increased and prolonged ocular surface contact and drug absorption.",
author = "Kim, {Yoo Chun} and Shin, {Matthew D.} and Hackett, {Sean F.} and Hsueh, {Henry T.} and {Lima e Silva}, Raquel and Abhijit Date and Hyounkoo Han and Kim, {Byung Jin} and Amy Xiao and Youngwook Kim and Laolu Ogunnaike and Anders, {Nicole M.} and Avelina Hemingway and Ping He and Jun, {Albert S.} and McDonnell, {Peter J.} and Charles Eberhart and Ian Pitha and Zack, {Donald J.} and Campochiaro, {Peter A.} and Justin Hanes and Ensign, {Laura M.}",
note = "Funding Information: The authors thank D. Guyton for sharing his expertise in light refraction, F. Selaru and L. Li for assistance with the swine animal protocol, and the veterinary and husbandry staff for their assistance. This work was supported by the National Institutes of Health (NIH) (grant nos. R01EB016121, R01EY026578 and P30EY001765), the Robert H. Smith Family Foundation, Guerrieri Family Foundation, a Sybil B. Harrington Special Scholar Award and a departmental grant from Research to Prevent Blindness, the KKESH–WEI Collaborative Research Fund, and a Hartwell Foundation Postdoctoral Fellowship. Drug measurements were conducted by the Analytical Pharmacology Core of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The work conducted by the Analytical Pharmacology Core was supported by the NIH grants P30CA006973, S10RR026824 and S10OD020091, as well as grant number UL1TR001079 and UL1TR003098 from the National Center for Advancing Translational Sciences, a component of the NIH, and the NIH Roadmap for Medical Research. This paper and its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Advancing Translational Sciences or the NIH. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = nov,
day = "1",
doi = "10.1038/s41551-020-00606-8",
language = "English (US)",
volume = "4",
pages = "1053--1062",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "11",
}